CARSGEN-B_Providing professional financial news and data related to CARSGEN-B, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

CARSGEN-B(02171.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 66.66 million, loss narrowed by 11.52% YoY

Tags：

CARSGEN-B 02171.HK loss narrowed

2026-08-19

CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma

Tags：

CARSGEN-B 02171.HK R&D Progress

2026-08-07

CARsgen Therapeutics (02171.HK) CT041 Postoperative Adjuvant Therapy Study Results Accepted for ESMO 2026 Poster Presentation

Tags：

CARSGEN-B 02171.HK biopharmaceutical

2026-07-15

CARSGEN-B(02171.HK): Kailimei® Secures NMPA Marketing Approval, the World’s First CAR-T Cell Therapy for Solid Tumors

Tags：

CARSGEN-B 02171.HK New Drug Application

2026-06-22

CARSGEN-B (02171.HK) plans to issue up to 23.7 million shares by placement, with estimated net proceeds of HKD 461.96 million

Tags：

CARSGEN-B 02171.HK Issue shares

2026-05-15

CARSGEN-B(02171.HK) closed 8.18% higher, The full-day turnover stood at HKD 190.55 million

Tags：

CARSGEN-B 02171.HK NewTimeSpace

2026-05-07

Scan QR Code

Download App